EXCLUSIVE LICENSE AGREEMENT by and between FIBROGEN, INC. andExclusive License Agreement • November 9th, 2021 • Fibrogen Inc • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 16, 2021 (the “Effective Date”) by and between FIBROGEN, INC., a company organized under the laws of Delaware with a business address at 409 Illinois Street, San Francisco, CA 94158, United States and its Affiliates (collectively, “FIBROGEN”), and ELUMINEX BIOSCIENCES (SUZHOU) LIMITED, a company organized under the laws of People’s Republic of China with registered address at Unit E421, Building 5, 218 Sangtian Street, Suzhou Industrial Park, Suzhou, Jiangsu, 215000, People’s Republic of China, (“ELUMINEX”). ELUMINEX and FIBROGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Re: Transition AgreementTransition Agreement • November 9th, 2021 • Fibrogen Inc • Pharmaceutical preparations • California
This letter sets forth the terms of the transition agreement (the “Agreement”) which you and FibroGen, Inc. (the “Company”) have agreed in the context of your employment transition.
